Marketing Opportunities:
The global pain market continues to be defined by large clinical unmet need, double digit annual growth, and current product offerings that leave an opportunity for improved pain management solutions. Over 40 million people in the U.S. suffer from chronic pain that manifests in a range of illnesses including osteoarthritis, HIV/AIDS, cancer, MS, and opiate addiction. Research indicates that more than 11 million Americans report pain as a significant disability. Patient pain needs have driven the growth of the transdermal pain drug delivery market which Jain PharmaBiotech reports was valued at $13 Billion in 2004 and is estimated to continue its growth trajectory to $32 Billion in 2015. The neuropathic pain market is forecasted to double to over $7 billion by 2016.
As of 2009, more than 27 million Americans suffered from osteoarthritis and supported the reported $5 Billion global and $2.6 Billion US sales markets [1]. In 2009, the US opioid market was valued at more than $11.1 Billion and is forecasted to reach more than $15.3 Billion by 2016 [2]. Rheumatoid arthritis affects approximately 0.5-1% of the United States population, and autoimmune diseases in general affect more than 20 million Americans. AllTranz has future plans to pursue clinical trials for adjunct treatment for rheumatoid arthritis and joint pain secondary to other autoimmune diseases, such as inflammatory bowel disease, multiple sclerosis, and systemic lupus erythematosus. A proof of concept clinical trial in acute plan is also planned.
[1] GlobalData, Osteoarthritis - Drug Pipeline Analysis and Market Forecasts to 2016, March 2010
[2] Frost and Sullivan, U.S. Opioid Pain Management Market, July 2010